TY  - JOUR
AU  - Awwad, Mohamed H S
AU  - Mahmoud, Abdelrahman
AU  - Bruns, Heiko
AU  - Echchannaoui, Hakim
AU  - Kriegsmann, Katharina
AU  - Lutz, Raphael
AU  - Raab, Marc-Steffen
AU  - Bertsch, Uta
AU  - Munder, Markus
AU  - Jauch, Anna
AU  - Weisel, Katja
AU  - Maier, Bettina
AU  - Weinhold, Niels
AU  - Salwender, Hans Jürgen
AU  - Eckstein, Volker
AU  - Hänel, Mathias
AU  - Fenk, Roland
AU  - Dürig, Jan
AU  - Brors, Benedikt
AU  - Benner, Axel
AU  - Müller-Tidow, Carsten
AU  - Goldschmidt, Hartmut
AU  - Hundemer, Michael
TI  - Selective elimination of immunosuppressive T cells in patients with multiple myeloma.
JO  - Leukemia
VL  - 35
IS  - 9
SN  - 1476-5551
CY  - London
PB  - Springer Nature
M1  - DKFZ-2021-00415
SP  - 2602-2615
PY  - 2021
N1  - 2021 Sep;35(9):2602-2615
AB  - Elimination of suppressive T cells may enable and enhance cancer immunotherapy. Here, we demonstrate that the cell membrane protein SLAMF7 was highly expressed on immunosuppressive CD8+CD28-CD57+ Tregs in multiple myeloma (MM). SLAMF7 expression associated with T cell exhaustion surface markers and exhaustion-related transcription factor signatures. T cells from patients with a high frequency of SLAMF7+CD8+ T cells exhibited decreased immunoreactivity towards the MART-1aa26-35*A27L antigen. A monoclonal anti-SLAMF7 antibody (elotuzumab) specifically depleted SLAMF7+CD8+ T cells in vitro and in vivo via macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). Anti-SLAMF7 treatment of MM patients depleted suppressive T cells in peripheral blood. These data highlight SLAMF7 as a marker for suppressive CD8+ Treg and suggest that anti-SLAMF7 antibodies can be used to boost anti-tumoral immune responses in cancer patients.
LB  - PUB:(DE-HGF)16
C6  - pmid:33597728
DO  - DOI:10.1038/s41375-021-01172-x
UR  - https://inrepo02.dkfz.de/record/167550
ER  -